Similarly, CRISPR knockout or RNAi knockdown of MASTL also reduced growth of some but not all breast cancer cell lines in vitro and in vivo (Vera et al., 2015; Álvarez-Fernández et al., 2018), suggesting that additional biomarkers will be needed for successful monotherapy. The gene discussed is MASTL; the disease is breast cancer.